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Abstract Peptide-Gold nanoparticles selectively attached
to b-amyloid protein (Ab) amyloidogenic aggregates were
irradiated with microwave. This treatment produces dra-
matic effects on the Ab aggregates, inhibiting both the
amyloidogenesis and the restoration of the amyloidogenic
potential. This novel approach offers a new strategy to
inhibit, locally and remotely, the amyloidogenic process,
which could have application in Alzheimer’s disease
therapy. We have studied the irradiation effect on the
amyloidogenic process in the presence of conjugates pep-
tide-nanoparticle by transmission electronic microscopy
observations and by Thioﬂavine T assays to quantify
the amount of ﬁbrils in suspension. The amyloidogenic
aggregates rather than the amyloid ﬁbrils seem to be better
targets for the treatment of the disease. Our results could
contribute to the development of a new therapeutic strategy
to inhibit the amyloidogenic process in Alzheimer’s
disease.
Keywords Alzheimer’s disease   Therapy   Aggregation  
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Introduction
Protein misfolding and aggregation in general and amylo-
idogenesis in particular are of growing interest as scientists
recognize their role in devastating degenerative diseases
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DOI 10.1007/s11671-008-9178-5such as Alzheimer’s and Parkinson’s disease. Protein and
peptide aggregation into mature amyloid ﬁbrils is a mul-
tistep process initiated by conformational changes with
samplings of preﬁbrillar intermediate amyloidogenic
aggregates (PIAA), such as oligomers, protoﬁbrils, pores,
amylospheroids, and short ﬁbrils [1]. Alzheimer0s disease is
a neurodegenerative disorder characterized by the presence
of extracellular deposits of amyloid protein and plaques in
the brain, composed primarily of toxic aggregates (PIAA
and amyloid ﬁbrils) of b-amyloid protein (Ab)[ 2]. In a
recent report, we demonstrated the feasibility of remote
deposit redissolving by using the local heat dissipated by
gold nanoparticles (AuNP) selectively attached to the Ab
ﬁbrils when irradiated with microwaves (MW) [3–5].
Although the mature ﬁbril was once assumed to be the
biologically toxic species, it has recently been hypothe-
sized that soluble intermediates such as PIAA are most
damaging [6–8]. Recently, several authors have hypothe-
sized that the key to an early pathogenic event in the onset
of Alzheimer’s disease is likely the formation of amyloi-
dogenic species rather than the amyloid ﬁbrils. A strategy
for the treatment of the disease could be reducing the
amyloidogenicity of this species [9, 10]. In an early stage,
this inhibition is of major importance to develop a potential
strategy for treating the Alzheimer’s disease. Thus, the
current study intends to demonstrate that the inhibition of
the aggregation process of b-amyloid in vitro by applying
weak microwave ﬁelds (0.1 W) is possible in the presence
of AuNP.
Could MW and AuNP Treatment Halt
the Amyloidogenic Process of PIAA?
Medical application of MW began in the 1970s [11]. In
animals and humans, local MW exposure stimulates tissue
repair and regeneration, alleviates stress reactions, and
facilitates recovery in a wide range of diseases [12]. MW
also modulates the effect of X-rays at both cellular and
organism levels. Diseases reported to be successfully
treated with MW are gastric, duodenal ulcers, cardiovas-
cular diseases, respiratory sickness, tuberculosis, skin
diseases, etc. [13]. MW irradiation with low-power density
also stimulates the immune potential of macrophages and T
cells [14]. On the other side, more intense MW ﬁelds
produce effects such as conformational changes and
denaturation processes on proteins [15]. The use of MW
and AuNP to produce local and remote heating is a pow-
erful tool for the development of new strategies to
manipulate the aggregation state of toxic proteins [3, 4].
Irradiation has been extensively explored as a means of
remote heating of biological tissues mediated by inorganic
nanoparticles [16]. In this study, we selectively bound
AuNP to Ab1–42 PIAA (Ab PIAA) and investigated the
effect of MW irradiation on the amyloidogenic process. To
allow selective attachment to PIAA, AuNPs were linked to
peptide CLPFFD, which contains the LPFFD sequence
that attaches selectively to the amyloidogenic Ab1–42
structures, forming the conjugate AuNP-CLPFFD. LPFFD
recognizes a particular (hydrophobic) domain of the
b-sheet structure [17].
Methods
CLPFFD Synthesis
CLPFFD was synthesized following ﬂuorenylmethyloxy-
carbonyl (Fmoc) strategy and solid phase synthesis
where the peptide is C-termed with an amide (CLPFFD-
NH2). Fmoc-protected amino acids were purchased from
Novabiochem (Laufelﬁngen, Switzerland) and Perseptive
Biosystems (Framingham, Massachusetts). O-(Benzotriazol-
1-yl)-N,N,N0,N0-tetramethyluronium tetraﬂuoroborate (TBTU),
Fmoc-AM handle, and resin MBHA were also obtained
from Novabiochem. Chemical reagents N,N0-diisopro-
pylcarbodiimide (DIPCI), 1-Hydroxy-1H-Benzotriazole
(HOBt), triethylsilane, and dimethylaminopyridine
(DMAP) were from Fluka (Buchs, Switzerland). Manual
synthesis included the following steps: (i) resin washing
with DMF (5 9 30 s); (ii) Fmoc removal with 20%
piperidine/DMF (1 9 1m i n? 2 9 7 min); (iii) washing
with DMF (5 9 30 s); (iv) washing with DMF (5 9 30 s)
and CH2Cl2 (5 9 30 s); (v) Kaiser’s test (with a peptide-
resin sample); (vi) DMF washing (5 9 30 s). Cleavage of
the peptide was carried out by acidolysis with triﬂuoro-
acetic acid (TFA) using triethylsilane and water as
scavengers (94:3:3, v/v/v) for 60–90 min. TFA was
removed with N2 stream and the oily residue precipitated
with dry tert-butyl ether. Peptide crude was recovered by
centrifugation and decantation of the tert-butyl ether
phase. The solid was redissolved in (water:acetonitrile
1:1) and lyophilized. The peptide was analyzed by
RP-HPLC [Waters 996 photodiode array detector
(k = 443 nm) equipped with a Waters 2695 separation
module (Milford, MA), a Symmetry column (C18, 5 lm,
4.6 9 150 mm), and Millennium software; ﬂow rate =
1 mL/min, gradient = 5–100% B over 15 min (A =
0.045% TFA in H2O, and B = 0.036% TFA in acetoni-
trile)]. The peptide was puriﬁed by semipreparative RP-
HPLC [Waters 2487 Dual Absorbance Detector equipped
with a Waters 2700 Sample Manager, a Waters 600
Controller, a Waters Fraction Collector, a Symmetry
column (C18, 5 lm, 30 9 100 mm
2), and Millennium
software]. The peptide was ﬁnally characterized by amino
acid analysis with a Beckman 6300 analyzer and by
MALDI-TOF with a Bruker model Biﬂex III. The result
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123of the amino acid analysis of CLPFFD-NH2 was Asp 1.0
( 1 ) ,P r o0 . 9 7( 1 ) ,L e u1 . 0( 1 ) ,P h e2 . 0 3( 2 ) ,a n di nt h em a s s
spectrum MALDI-TOF of CLPFFD-NH2, the peaks
[M
?H
?] = 740 and [M
?Na
?] = 762 were found.
AuNP Synthesis
Citrate-coated AuNP (12.5 ± 1.7 nm) were prepared by
citrate reduction of HAuCl4 in accordance with Ref. [4].
An aqueous solution of HAuCl4 (100 mL, 1 mM) was
reﬂuxed for 5–10 min, and a warm (50–60 C) aqueous
solution of sodium citrate (10 mL, 38.8 mM) was added
quickly [3]. Reﬂux was continued for another 30 min until
a deep red solution appeared. The solution was ﬁltered
through 0.45 lm Millipore syringe ﬁlters to remove any
precipitate, the pH was adjusted to 7.4 using dilute NaOH
solution, and the ﬁltrate was stored at 4 C. AuNPs were
observed by Transmission Electronic Microscopy (TEM)
using a JEOL JEM-1010 microscope. The specimen was
prepared by dropping AuNP on formvar carbon-coated
copper microgrids and letting them dry.
Conjugation of CLPFFD with AuNP
AuNP-CLPFFD was prepared by mixing 5 nM AuNP and
peptide CLPFFD solution (1 mg/ml) in a volume ratio 10
to 1. The conjugation was made in the presence of excess
peptide to ensure full conversion of the AuNP and,
consequently, homogeneous conjugation. The conjugate
AuNP-CLPFFD was afterwards puriﬁed ﬁrst in a 450 nm
ﬁlter and then by dialysis (for 3 days in a membrane
Spectra/Por MWCO: 6–8000 against 1.2 mM sodium cit-
rate and the solution was changed 6 times) to eliminate the
excess of peptide. UV–vis absorption spectra were recor-
ded at room temperature with a Unicam UV/Vis
spectrophotometer (UV3). To verify that after dialysis the
non-conjugated peptide was completely eliminated, two
experiments were performed:
(a) After dialysis, 3 mL of AuNP-CLPFFD was centri-
fuged at 16,000g for 30 min (AuNP-CLPFFD
sediments) and the supernatant was evaporated to
dryness, and an analysis of amino acids and HPLC
ES-MS were carried out. In both cases, the presence
of the peptide was not detected.
(b) The AuNP-CLPFFD pellet obtained after dialysis and
centrifugation was washed twice with 300 lLo f1 %
TFA. For washing, the pellet was redissolved and
centrifuged at 16,000g for 30 min (this treatment
allows the detachment of non-covalent molecules that
could be retained and non-covalently attached to
AuNP-CLPFFD pellet). In the supernatant, free
peptide was not detected by HPLC ES-MS, which
indicates that after dialysis the free peptide was
completely eliminated. It is important to mention that
washing with a dilute solution of triﬂuoroacetic acid,
1% TFA, does not provoke the cleavage of CLPFFD
from the AuNP-CLPFFD conjugate.
Characterization of Conjugates AuNP-CLPFFD
X-ray photoelectron spectroscopy (XPS) experiments were
performed in a PHI 5500 multitechnique System (from
Physical Electronics) with a monochromatic X-ray source
(Aluminum Kalfa line of 1486.6 eV energy and 350 W),
placed perpendicular to the analyzer axis and calibrated
using the 3d5/2 line of Ag with a full width at half maxi-
mum (FWHM) of 0.8 eV. The analyzed area was a circle
of 0.8 mm diameter, and the selected resolution for the
spectra was 187.5 eV of Pass Energy and 0.8 eV/step
for the general spectra and 23.5 eV of Pass Energy and
0.1 eV/step for the spectra of the different elements. Some
measurements were done after some cleaning by sputtering
the surface with an Ar
? ion source (4 keV energy). All
measurements were made in an ultra high vacuum chamber
pressure between 5 9 10
-9 and 2 9 10
-8 Torr. In AuNP-
CLPFFD, the expected peaks from S 2p, S 2s, and Au 4f
core levels were detected. High-resolution data have also
been recorded in the S 2p, S 2s, and Au 4f, spectral regions.
The S 2p signal consists of a broad band with a maximum
at 162.2 eV that corresponds to the chemisorptions of
sulfur grafted onto gold. The experimental curve ﬁtted with
the signals S 2p3/2 and S 2p1/2 (162.1 and 163.3 eV sig-
nals, respectively) that correspond to a doublet for sulfur
atoms bound to gold (supplementary data). According to
our calculations, the signal of 164 eV was not found in this
peak, which led us to conclude that unbound S species are
not present in the samples. In addition, the S 2s photo-
electron peak was observed. This peak is a particularly
good parameter since it is a singlet, thus making the
interpretation straightforward. The S 2s photoelectron
binding energy (BE) from bulk peptide with the free thiol
and AuNP peptide thiolate are found at 228.2 and 227.3,
respectively. The accuracy of these BE values is estimated
to be ±0.2 eV at the worst. In the case of bare AuNP and
capped AuNP, the signal corresponding to Au 4f7/2 is
positioned at 84.2 eV. The fact that the measured Au 4f7/2
photoelectron BE is not detected by the sulfur chemisorp-
tion is probably because the peak separation is too small.
Estimation of the Number of Peptide Attached
Molecules per AuNP
The amount of peptide molecule per NP was estimated by
analysis of amino acids and absorption spectrophotometry.
Nanoscale Res Lett (2008) 3:435–443 437
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taking into account the molar coefﬁcient of extinction of
the 12 nm diameter (5.7 9 107 M
-1 cm
-1) AuNP and an
analysis of amino acids of the pellet obtained after cen-
trifugation of the conjugates at 13,500 rpm for 30 min (in
such conditions, the NP sediment). In the amino acid
analysis, a hydrolysis of the peptide conjugated to the
AuNP (the non-conjugated peptide was eliminated in
Section ‘‘Conjugation of CLPFFD with AuNP’’) was per-
formed; thus it was possible to determine the concentration
of attached peptide molecules. The number of peptide
molecules per AuNP was obtained by dividing the number
of peptide molecules per mL of solution by the number of
particles per mL of solution. This ratio was obtained in
triplicate in three independent syntheses and conjugations.
The degree of conjugation of AuNP-CLPFFD is 460 ± 30
peptide molecules per AuNP.
Preparation of Ab PIAA Solutions
Ab1–42 was purchased from r-Peptide (USA). About 1 mg
peptide was suspended in water (1 mL) and this suspension
was divided in 10 aliquots. Peptide aliquots were lyophi-
lized in glass vials and stored at -20 C. To obtain a
homogeneous Ab1–42 solution free from aggregates, the
peptide was treated with 200 lL of 1,1,1,3,3,3-hexaﬂuoro-
2-propanol (HFIP) for 30 min at room temperature. The
HFIP was then lyophilized and the peptide was dissolved in
water to obtain a 400 lL solution of Ab PIAA [18].
Ab PIAA/AuNP-CLPFFD and Controls for Irradiation
Sodium citrate, AuNP, AuNP-CLPFFD, or CLPFFD were
added to the Ab PIAA and the samples were incubated for
25 min at room temperature. We irradiated two samples
with different ratio of Ab/AuNP-CLPFFD (10 lM:1 nM
and 10 lM:0.2 nM) and the controls.
Samples
Ab PIAA/1 nM AuNP-CLPFFD Samples were prepared by
mixing 12.5 lL of 400 lMA b,1 0 0lL of 5 nM AuNP-
CLPFFD, and 388 lL of sodium citrate 1.2 mM.
AbPIAA/0.2 nMAuNP-CLPFFDSampleswereprepared
by mixing 12.5 lL of 400 lMA b PIAA, 20 lLo f5n M
AuNP-CLPFFD, and 468 lL of sodium citrate 1.2 mM.
Controls
For the irradiation process we used three controls: (1) Ab
PIAA, a solution of PIAA (12.5 lL of 400 lMA b) was
mixed with 487.5 lL of sodium citrate 1.2 mM; (2) Ab
PIAA ? AuNP, a solution of PIAA (12.5 lL of 400 lM
Ab) was mixed with 100 lL of 5 nM AuNP and 388 lLo f
sodium citrate 1.2 mM; (3) Ab PIAA ? CLPFFD, a
solution of Ab PIAA (12.5 lL of 400 lMA b) was mixed
with 26 lL of 7.8 lM CLPFFD and 461.5 lL of sodium
citrate 1.2 mM. The ratio CLPFFD to Ab (1:24.5) is not
enough to inhibit the ﬁbril growth.
Irradiation
We used an HP HP83651B signal generator, working in a
frequency range from 10 MHz to 50 GHz with a signal
modulator HP8510C for determining the working fre-
quency and power. Power was 100 mW. We apply the
microwaves in a resonating chamber under mild magnetic
stirring. The resonating chamber was a copper cavity of
6 cm diameter by 12 cm height with 0.5 cm thick
walls. Microwaves arrived from the top through a wave-
guide while another waveguide read the signal inside the
chamber. A resonant peak was chosen. Samples were
introduced, and inside each vial a magnetic stirrer was
introduced and the samples stirred for homogeneity.
Samples and controls were irradiated for 10 and 30 min
and then were centrifuged at 16,000g for 1 min and ﬁnally
observed by TEM. Irradiated samples were incubated at
room temperature for 48 h, and the ﬁbril formation was
determined by ThT test and by TEM.
Incubation of Irradiated Samples and Controls for Fibril
Formation
The irradiated samples and controls and non-irradiated
samples and controls were incubated at room temperature
for 48 h to form amyloid ﬁbrils.
Determination of Fibril Formation
Thioﬂavine T-test
Glycine 0.1 M buffer pH = 8.4 was introduced in 384
Nunc well ﬂuorescence microliter plates and samples were
added and mixed. Then Thioﬂavin T (100 lM) was added
and mixed. The ﬁnal peptide and Thioﬂavine T concen-
tration is 4 lM. The ﬂuorescence signal was measured
(excitation wavelength 440 ± 10 nm) in a FL600 Micro-
plate Fluorescence reader with KC4 version 2.7 software
Biotek instruments, INC.
Transmission Electronic Microscopy
Aliquots of 10 lL (10 lMd eA b) of the preparations were
adsorbed for 1 min onto glow-discharged carbon-coated
collodium ﬁlms on 200-mesh copper grids. The TEM grids
were then blotted and washed twice in distilled H2O before
438 Nanoscale Res Lett (2008) 3:435–443
123staining with uranyl acetate 2% for 2 min for visualization
by TEM (JEOL JEM-1010).
Results and Discussion
We prepared Ab PIAA with high amyloidogenic capacity
according with Bieschke et al. [18]. The Ab PIAA was
incubated with AuNP-CLPFFD, forming the complex Ab
PIAA/AuNP-CLPFFD. The samples were then irradiated in
a copper resonating chamber using a 14-GHz RF signal and
100 mW power. Ab PIAA (10 lM) was mixed with
AuNP-CLPFFD in two different ratios and the resulting
complexes were characterized by TEM observing the typ-
ical PIAA structures, i.e., amylospheroids, protoﬁbrils, and
short ﬁbrils attached and non-attached to AuNP-CLPFFD
depending of the Ab PIAA/AuNP-CLPFFD ratios (sup-
plementary data, FS1). These complexes were irradiated
for different times. After irradiation of Ab PIAA/AuNP-
CLPFFD samples, amorphous aggregate structures instead
of the typical Ab PIAA (amylospheroids, protoﬁbrils, and
short ﬁbrils) were visualized by TEM (supplementary data,
FS2). To determine whether Ab PIAA lost the amyloido-
genic potential, the irradiated samples were incubated for
48 h at room temperature to allow ﬁbril formation and
assess whether the amyloidogenic capacity of PIAA is
altered. Thioﬂavine T (ThT) assays were performed to
quantify the amount of ﬁbrils in suspension, observing a
ﬂuorescence signal proportional to the amount of formed
ﬁbrils [19]. Figure 1 exhibits the ﬂuorescence signal of
irradiated samples and respective controls. A lower ﬂuo-
rescence signal was observed in Ab PIAA/AuNP-CLPFFD
complex samples compared with controls (Fig. 1). In
addition, the irradiated sample (Ab PIAA/AuNP-CLPFFD)
incubation at room temperature was followed for 1 month
but the intensity of ﬂuorescence did not increase, which
demonstrated that the ﬁbrillogenic process had stopped
(data not shown).
In samples irradiated for 10 min, a low ﬂuorescence
intensity signal was observed after 48 h of incubation
(Fig. 1); some ﬁbrils were visualized by TEM, which
indicate that the irradiation time (10 min) was not enough
to halt the amyloidogenic process (supplementary data,
FS3). The halting of the ﬁbrillogenic process is a con-
centration- and irradiation time-dependent phenomenon
(supplementary data, FS3). Fibril formation was detected
in irradiated samples with a high Ab:AuNP-CLPFFD ratio
(10 lM:0.2 nM) for 10 and 30 min (Fig. 2 and supporting
material, FS3) but ﬁbril formation was not detected using a
ﬁnal Ab:AuNP-CLPFFD ratio of 10 lM: 1 nM and 30 min
of irradiation (Figs. 1 and 3).
Figure 3 shows TEM micrographs of the sample Ab
PIAA/AuNP-CLPFFD complex and controls before and
after irradiation for 30 min and further incubation (right),
and non-irradiated and incubated sample and controls
(left). The complex Ab PIAA/AuNP-CLPFFD (Fig. 3b)
was irradiated (Fig. 3c) and after incubation no ﬁbril for-
mation was observed (Fig. 3d). In contrast, in control
experiments with irradiation, the ﬁbril formation process
was not interrupted (Fig. 3h, l, and p). We also carried out
0
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Fig. 1 Intensity of ThT ﬂuorescence signal of Ab PIAA/AuNP-
CLPFFD sample (10 lMA b PIAA:1 nM AuNP-CLPFFD) and
controls (Ab PIAA, Ab PIAA ? CLPFFD, Ab PIAA ? bare AuNP)
irradiated for 10 and 30 min and then incubated for 48 h
Fig. 2 Intensity of thioﬂavine T ﬂuorescence signal of Ab PIAA/
AuNP-CLPFFD sample (10 lMA b PIAA:0.2 nM AuNP-CLPFFD)
and controls Ab PIAA (10 lM), Ab PIAA ? CLPFFD, Ab
PIAA ? bare AuNP (Ab 10 lM: 0.2 nM AuNP), irradiated for 10
and 30 min and then incubated for 48 h
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123control experiments to determine whether the presence of
AuNP-CLPFFD, bare AuNP, or CLPFFD alone interfered
with the normal ﬁbrillogenic process of Ab PIAA in the
absence of irradiation (Fig. 3, left). In these cases, ﬁbril
formation was not inhibited (Figs. 3a, e, i, m, and 4). After
irradiation of Ab PIAA/AuNP-CLPFFD samples, non-
characteristic structures corresponding to typical Ab PIAA
were visualized by TEM (Fig. 3c and additional ﬁgures in
supplementary data, FS2). Irradiation in the presence of
AuNP-CLPFFD produced dramatic effects on Ab PIAA
and consequently on the amyloidogenesis.
We studied the restoring of the amyloidogenic potential
of irradiated Ab PIAA/AuNP-CLPFFD after a denaturing
treatment with 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP)
and incubation in water. Figure 5 shows a TEM micrograph
of an irradiated Ab PIAA/AuNP-CLPFFD sample before
(Fig. 5a) and after (Fig. 5b) HFIP and incubation treatment
and a non-irradiated control before (Fig. 5c) and after
(Fig. 5d) HFIP and incubation treatment. Irradiation of Ab
PIAA/AuNP-CLPFFD provokes an irreversible effect that
avoids restoration of Ab ﬁbrils formation in contrast to non-
irradiated controls as summarized in Scheme 1.
Fig. 3 TEM micrographs of Ab
PIAA/AuNP-CLPFFD sample
and controls (starting
conditions: b, f, j, and n,
respectively). Sample and
controls after irradiation for
30 min (c, g, k, and o,
respectively) and incubated for
48 h at room temperature (d, h,
l, and p, respectively). Non-
irradiated sample and controls
incubated for 48 h (a, e, i, and
m, respectively). Bars represent
200 nm
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Fig. 4 Intensity of thioﬂavine T ﬂuorescence signal of non-irradiated
Ab PIAA/AuNP-CLPFFD sample (10 lMA b PIAA:1 nM AuNP-
CLPFFD) and controls Ab PIAA (10 lM), Ab PIAA ? CLPFFD, Ab
PIAA ? bare AuNP (Ab 10 lM: 0.2 nM AuNP), stirred magnetically
for 30 min and incubated for 48 h
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CLPFFD Complex be Incorporated During Fibril
Growth of Fresh Ab PIAA?
We added fresh Ab PIAA to both Ab PIAA/AuNP-
CLPFFD irradiated complex (sample) and Ab PIAA/
AuNP-CLPFFD non-irradiated complex (control), and
incubated the resulting mixture for additional 48 h, deter-
mining ﬁbril formation by ThT assay and by TEM.
Figure 6a shows the time course of the ﬂuorescence signal
of sample and control. Although both have the same total
Ab concentration, ﬁbril formation is lower in the former.
The intensity of the ﬂuorescence signal of the sample could
be attributed only to ﬁbril formation of the freshly added
Ab PIAA, while in control, the ﬁnal ﬂuorescence intensity
corresponds to the addition of freshly added Ab PIAA and
Ab PIAA/AuNP-CLPFFD together. Therefore, the species
formed after irradiation are not amyloidogenic per se and
they do not promote the formation of amyloid ﬁbrils from
freshly added Ab PIAA solution either. Figure 6b–d shows
ﬁbril formation after freshly added Ab PIAA aggregation
in the presence of irradiated Ab PIAA/AuNP-CLPFFD.
Figure 6 shows that irradiated Ab PIAA/AuNP-CLPFFD
(Fig. 6b) are not bounded to ﬁbrils (Fig. 6d), suggesting
that irradiation of aggregates doped with AuNP-CLPFFD
changes their structure in such a way that the new structure
cannot be bound to the growing ﬁbrils. In contrast, in non-
irradiated control, Ab PIAA/AuNP-CLPFFD is incorpo-
rated to the ﬁbrils (Fig. 6 f, g), showing that AuNP-
CLPFFD incorporation does not affect their growth. In
conclusion, we can infer that the structure of Ab PIAA/
AuNP-CLPFFD is dramatically altered after irradiation and
cannot be incorporated or bound to new Ab ﬁbrils.
Summing up, MW and AuNP linked to a peptide that
selectively attaches to amyloidogenic Ab1–42 structures
inhibit irreversibly their normal aggregation. The resulting
irradiated products are not amyloidogenic. Our approach
provides a viable means to inhibit irreversibly the
Fig. 5 TEM micrographs of
irradiated sample of Ab PIAA/
AuNP-CLPFFD before (a) and
after (b) treatment with HFIP
and incubation for 48 h. Non-
irradiated control (Ab PIAA/
AuNP-CLPFFD) before (c) and
after (d) treatment with HFIP
and incubation for 48 h. Bars
represent 200 nm
A 1-42
Lyophilization
Water
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AP I A A
Non fibril formation
Lyophilization
Water
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Fibril Formation Aβ PIAA
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48 h
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Incubation
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X X
Incubation 48 h
Incubation
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Scheme 1 Irreversible
inhibition of the amyloidogenic
process of Ab PIAA mediated
by AuNP-CLPFFD and MW
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123amyloidogenic process of Ab. Further investigations in our
laboratory include an assessment of the irradiation effect
on Ab structure and potential toxicity. This tool could be
used for therapeutical purposes by inhibiting locally and
remotely the amyloidogenic process of proteins.
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